Lipoprotein apheresis for the treatment of familial hypercholesterolemia

References

• Thompson GR, Lowenthal R, Myant R. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1, 1208–1211 (1975).
   Google Scholar
• Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, Steiner RE. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br. Heart J. 43, 680–688 (1980).
   Google Scholar
• Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br. Med. J. 291, 1671–1673 (1985). ▪ First description of increased survival of homozygotes treated with plasma exchange.
   Google Scholar
• Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 2, 1005–1007 (1981). ▪ First description of selective lipoprotein (Lp) apheresis.
   Google Scholar
• Thompson GR. Lipoprotein apheresis. Curr. Opin. Lipidol. 21, 487–491(2010).
   Google Scholar
• Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 5, 613–622 (1985).
   Google Scholar
• Mabuchi H, Michishita I, Takeda M et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 68, 19–26 (1987).
   Google Scholar
• Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system. Klin. Woch. 65, 161–168 (1987).
   Google Scholar
• Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipid filtration – safe and effective methodology to perform lipid-apheresis. Transfus. Apher. Sci. 30, 245–254 (2004).
   Google Scholar
• Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W. LDL hemoperfusion – a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis in patients. Artif. Organs 21, 1060–1065 (1997).
   Google Scholar
• Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R, Geiss HC. Dextran-sulfateadsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis – comparison of performance characteristics with DALI and lipid filtration. J. Clin. Apher. 22, 215–223 (2007).
   Google Scholar
• Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42, 888–894 (1993).
   Google Scholar
• Pokrovsky SN, Sussekov AV, Afanasieva OI, Adamova IY, Lyakishev AA, Kukharchuk VV. Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data. Chem. Phys. Lipids 67–68, 323–330 (1994).
   Google Scholar
• Gordon BR, Kelsey SF, Dau PC et al.; Liposorber Study Group. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am. J. Cardiol. 81, 407–411 (1998).
   Google Scholar
• Krebs A, Krebs K, Keller F. Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. Int. J. Artif. Organs 27, 137–148 (2004).
   Google Scholar
• Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int. J. Artif. Organs 25, 1180–1188 (2002).
   Google Scholar
• Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif. Organs 17, 640–652 (1993).
   Google Scholar
• Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 198, 247–255 (2008). ▪ HEART‑UK guidelines for Lp apheresis.
   Google Scholar
• Richter WO, Donner MG, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther. Apher. 3, 203–208 (1999).
   Google Scholar
• Arends J, Bier DM, Schafer G et al. No evidence for feedback inhibition of hepatic apolipoprotein B (apoB) production after extracorporeal low density lipoprotein precipitation as determined by [1-13C] leucine infusion in normal volunteers. Eur. J. Clin. Invest. 23, 602–614 (1993).
   Google Scholar
• Thompson GR, Spinks T, Ranicar A, Myant NB. Non-steady state studies of low density-lipoprotein turnover in familial hypercholesterolaemia. Clin. Sci. Mol. Med. 52, 361–369 (1977).
   Google Scholar
• Parhofer KG, Barrett PH, Demant T, Schwandt P. Acute effects of low density lipoprotein apheresis on metabolic parameters of apoliprotein B. J. Lipid Res. 41, 1596–1603 (2000).
   Google Scholar
• Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 152, 519–526 (2000). ▪ Dutch description of a useful formula for calculating interval mean values.
   Google Scholar
• Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 208, 317–321 (2010).
   Google Scholar
• Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38, 2071–2078 (1997).
   Google Scholar
• Pfohl M, Naoumova RP, Klass C et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35, 1946–1955 (1994).
   Google Scholar
• Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler. Suppl. 10, 21–26 (2009).
   Google Scholar
• Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124, 2202–2207 (2011). ▪ Description of increased longevity of homozygotes treated with statins ± ezetimibe in South Africa.
   Google Scholar
• Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler. Suppl. 14(1), 67–70 (2013).
   Google Scholar
• Thompson GR, Maher VM, Matthews S et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 345, 811–816 (1995).
   Google Scholar
• Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93, 1826–1835 (1996).
   Google Scholar
• Nishimura S, Sekiguchi M, Kano T et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 144, 409–417 (1999).
   Google Scholar
• Mabuchi H, Koizumi J, Shimizu M et al. Hokuriku-FH-LDL Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am. J. Cardiol. 82, 1489–1495 (1998). ▪ Demonstration of reduced incidence of nonfatal coronary events in Japanese heterozygotes treated with apheresis plus drugs versus drugs alone.
   Google Scholar
• Kronenberg F, Utermann G. Lipoprotein (a): resurrected by genetics. J. Int. Med. 273, 6–30 (2013). ▪ Up‑to‑date and authorative review of the enigmatic lipoprotein, Lp(a).
   Google Scholar
• Armstrong VW, Cremer P, Eberle E et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 62, 249–257 (1986).
   Google Scholar
• Jaeger B, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat. Clin. Pract. Cardiovasc. Med. 6, 229–239 (2009). ▪ Retrospective analysis showing reduction in cardiovascular events in patients with raised Lp(a) treated with Lp apheresis in Germany.
   Google Scholar
• Emerging Risk Factors Collaboration. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412–423 (2009).
   Google Scholar
• Safarova MS, Ezhov MV, Afanasieva OI et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl. 14, 93–99 (2013). ▪ Russian study showing regression of coronary atherosclerosis on quantitative angiography following selective Lp(a) apheresis plus statin versus statin alone.
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421(2002).
   Google Scholar
• Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients. A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation 114, 2710–2738 (2006).
   Google Scholar
• Sczepiorkowski ZM, Bandarenko M, Kim HC et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J. Clin. Aph. 22, 106–175 (2007).
   Google Scholar
• Ito MK, McGowan MP, Moriarty PM. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S38–S45 (2011).
   Google Scholar
• Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur. Heart J. 19, 1434–1503 (1998).
   Google Scholar
• [Joint Federal Committee. Notice of Decision of the Federal Committee amending Directive methods contractual medical care: apheresis with isolated Lp(a) increase for study participants]. BAnz 128, 3005 (2009).
   Google Scholar
• Civiera F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173, 55–68 (2004).
   Google Scholar
• Stefanutti C. The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutr. Metab. Cardiovasc. Dis. 20, 761–762 (2010).
   Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844–2853 (2010).
   Google Scholar
• Harada-Shiba M, Arai H, Oikawa S et al. Guidelines for the management of familial hypercholesterolemia. J. Atheroscler. Thromb. 19, 1043–1060 (2012).
   Google Scholar
• NICE. Identification and Management of Familial Hypercholesterolaemia. Clinical Guideline 71. NICE, London, UK (2008).
   Google Scholar
• Gagné C, Gaudet D, Bruckert E et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105, 2469–2475 (2002).
   Google Scholar
• Palcoux JB, Atassi-Dumont M, Lefevre P et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther. Apher. Dial. 12, 195–201 (2008).
   Google Scholar
• Hudgins L, Kleimann B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1199–1204 (2008).
   Google Scholar
• Kolansky DM, Cuchel M, Clark BJ et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1438–1443 (2008).
   Google Scholar
• Graesdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J. Clin. Lipidol. 6, 331–339 (2012). ▪ An 11‑year follow‑up of seven Norwegian homozygotes undergoing weekly apheresis and maximal tolerable drug therapy from 9–10 years of age.
   Google Scholar
• Webb JC, Sun XM, McCarthy SM et al. Characterisation of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolaemia and frequency of these mutations in FH patients in the UK. J. Lipid Res. 37, 368–381 (1996).
   Google Scholar
• Rallides L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 80, 583–590 (1998).
   Google Scholar
• Descamps OS, Gilbeau JP, Luwaert R, Heller FR. Impact of genetic defects on coronary atherosclerosis in patients suspected of having familial hypercholesterolaemia. Eur. J. Clin. Invest. 33, 1–9 (2003).
   Google Scholar
• Sidhu PS, Naoumova RP, Maher VM et al. The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal–medial thickness and plaque morphology with plasma lipids and coronary heart disease. J. Cardiovasc. Risk 3, 61–67 (1996).
   Google Scholar
• Thompson GR. LDL apheresis. Atherosclerosis 167, 1–13 (2003).
   Google Scholar
• Berthold HK, Descamps OS, Gouni-Berthold I. Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity? Eur. J. Clin. Invest. 43, 108–112 (2013).
   Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, Phase 3 study. Lancet 381, 40–46 (2013). ▪▪ Phase III study showing additive effects of Lp apheresis and the MTP inhibitor lomitapide on LDL cholesterol in homozygotes.
   Google Scholar